Cantor Fitzgerald Forecasts Arcellx FY2026 Earnings

Arcellx, Inc. (NASDAQ:ACLX - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Arcellx in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will earn ($2.65) per share for the year. The consensus estimate for Arcellx's current full-year earnings is ($1.58) per share.

Separately, Scotiabank decreased their target price on Arcellx from $133.00 to $93.00 and set a "sector outperform" rating for the company in a research report on Friday, May 9th. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $111.33.

Arcellx Trading Down 0.4%

NASDAQ:ACLX traded down $0.25 during trading hours on Tuesday, hitting $66.61. 509,348 shares of the stock traded hands, compared to its average volume of 606,344. The firm has a 50 day moving average price of $61.33 and a 200 day moving average price of $68.42. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $107.37. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -93.82 and a beta of 0.28.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.29). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The firm had revenue of $8.13 million for the quarter, compared to analyst estimates of $19.51 million.

Insider Activity at Arcellx

In other news, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $57.50, for a total transaction of $86,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 6,000 shares of company stock valued at $377,655. Insiders own 8.35% of the company's stock.

Hedge Funds Weigh In On Arcellx

A number of hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Arcellx by 104.1% in the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company's stock valued at $32,000 after acquiring an additional 252 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Arcellx in the 4th quarter worth approximately $41,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Arcellx during the first quarter worth $50,000. GF Fund Management CO. LTD. bought a new stake in Arcellx in the fourth quarter valued at about $87,000. Finally, Amalgamated Bank boosted its stake in Arcellx by 12.0% in the 1st quarter. Amalgamated Bank now owns 1,508 shares of the company's stock valued at $99,000 after buying an additional 161 shares in the last quarter. Institutional investors and hedge funds own 96.03% of the company's stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).